Previous Close | 0.0100 |
YTD Return | N/A |
Expense Ratio (net) | N/A |
Category | N/A |
Last Cap Gain | N/A |
Morningstar Rating | N/A |
Morningstar Risk Rating | N/A |
Sustainability Rating | N/A |
Net Assets | N/A |
Beta (5Y Monthly) | N/A |
Yield | N/A |
5y Average Return | N/A |
Holdings Turnover | N/A |
Last Dividend | N/A |
Average for Category | N/A |
Inception Date | N/A |
Latest Peer-Reviewed Study Published in Frontiers in Public Health Highlights Cost-Efficiency and Improved Clinical Outcomes from Using Cognetivity's Proprietary CognICA(TM) Technology, Showing Savings of Over £40 Million Per Year Compared with Traditional Cognitive Assessment Tools in Primary and Secondary Care Vancouver, British Columbia--(Newsfile Corp. - October 24, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leader in ar
Collaboration With Highly Rated Healthcare Provider Opens US Healthcare Market for Brain Health for AI Powered CognICA, Enabling Patient Access to Latest Alzheimer's Drugs Vancouver, British Columbia--(Newsfile Corp. - October 11, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading artificial intelligence (AI) healthcare technology company is delighted to announce a collaboration with UC Health, one of the leading healthcare
Program Designed to Identify Age-Related Brain Health Issues at an Early Stage, Allowing Effective Provision of Coordinated Care Vancouver, British Columbia--(Newsfile Corp. - October 3, 2023) - Cognetivity Neurosciences Ltd. (CSE: CGN) (OTC Pink: CGNSF) (FSE: 1UB) ("the Company" or "Cognetivity"), a leading AI healthcare technology company, is delighted to announce a collaboration with the Mediclinic Group ("Mediclinic"), a prominent international private hospital group operating across Europe,